Profile data is unavailable for this security.
About the company
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. The Company is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead investigational product candidate, INT230-6, is designed for direct intratumoral injection. Its INT230-6 is primarily comprised of three components: cisplatin, vinblastine sulfate and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of Phase III open-label, randomized study testing the superiority of INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, and Phase II/III clinical study in metastatic triple negative breast cancer.
- Revenue in USD (TTM)0.00
- Net income in USD-16.26m
- Incorporated2012
- Employees5.00
- LocationIntensity Therapeutics Inc1 Enterprise Drive, Suite 430SHELTON 06484United StatesUSA
- Phone+1 (203) 221-7381
- Fax+1 (302) 636-5454
- Websitehttps://www.intensitytherapeutics.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Carisma Therapeutics Inc | 20.27m | -63.80m | 35.40m | 107.00 | -- | -- | -- | 1.75 | -1.56 | -1.56 | 0.4927 | -0.2665 | 0.2723 | -- | -- | 189,420.60 | -85.73 | -30.87 | -101.81 | -34.47 | -- | -- | -314.78 | -255.66 | -- | -- | -- | -- | -62.70 | -- | -336.93 | -- | 255.27 | -- |
| Elevation Oncology Inc | 0.00 | -41.95m | 35.78m | 29.00 | -- | 0.5159 | -- | -- | -0.807 | -0.807 | 0.00 | 1.17 | 0.00 | -- | -- | 0.00 | -40.67 | -- | -43.53 | -- | -- | -- | -- | -- | -- | -375.06 | 0.309 | -- | -- | -- | 51.93 | -- | -- | -- |
| NextCure Inc | 0.00 | -58.52m | 36.13m | 82.00 | -- | 0.4774 | -- | -- | -2.09 | -2.09 | 0.00 | 2.70 | 0.00 | -- | -- | 0.00 | -50.82 | -22.59 | -54.42 | -23.54 | -- | -- | -- | -964.96 | -- | -- | 0.00 | -- | -- | -- | 16.07 | -- | -23.17 | -- |
| CERo Therapeutics Holdings Inc | 0.00 | -2.54m | 36.58m | 8.00 | -- | -- | -- | -- | -0.3796 | -0.3796 | 0.00 | -0.9226 | 0.00 | -- | -- | 0.00 | -9.96 | -- | -33.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -279.82 | -- | -- | -- |
| Rapt Therapeutics Inc | 0.00 | -107.49m | 36.65m | 70.00 | -- | 0.3837 | -- | -- | -2.78 | -2.78 | 0.00 | 2.74 | 0.00 | -- | -- | 0.00 | -69.76 | -46.30 | -77.90 | -49.97 | -- | -- | -- | -3,522.72 | -- | -- | 0.00 | -- | -100.00 | -- | -39.31 | -- | -20.31 | -- |
| AN2 Therapeutics Inc | 0.00 | -60.70m | 36.75m | 41.00 | -- | 0.419 | -- | -- | -2.04 | -2.04 | 0.00 | 2.94 | 0.00 | -- | -- | 0.00 | -48.27 | -- | -53.56 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.33 | -- | -- | -- |
| Intensity Therapeutics Inc | 0.00 | -16.26m | 37.18m | 5.00 | -- | 13.47 | -- | -- | -1.18 | -1.18 | 0.00 | 0.2005 | 0.00 | -- | -- | 0.00 | -147.61 | -- | -171.25 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -56.45 | -- | -- | -- |
| OS Therapies Inc | 0.00 | -7.42m | 37.23m | 4.00 | -- | -- | -- | -- | -0.3566 | -0.3566 | 0.00 | -0.0334 | 0.00 | -- | -- | 0.00 | -559.23 | -- | -- | -- | -- | -- | -- | -- | -- | -2.13 | -- | -- | -- | -- | -24.09 | -- | -- | -- |
| Lumos Pharma Inc | 2.21m | -34.92m | 37.45m | 30.00 | -- | 7.62 | -- | 16.98 | -4.29 | -4.29 | 0.2705 | 0.5682 | 0.0676 | -- | 12.75 | 66,818.18 | -107.08 | -29.78 | -132.78 | -32.32 | -- | -- | -1,583.49 | -2,937.61 | -- | -- | 0.00 | -- | 34.67 | -30.31 | -9.57 | -- | -- | -- |
| Calidi Biotherapeutics Inc | 0.00 | -27.95m | 37.66m | 41.00 | -- | -- | -- | -- | -5.61 | -5.61 | 0.00 | -1.10 | 0.00 | -- | -- | 0.00 | -208.29 | -- | -2,279.15 | -- | -- | -- | -- | -- | -- | -28.13 | -- | -- | -100.00 | -- | -14.90 | -- | -- | -- |
| FibroGen Inc | 180.01m | -121.79m | 38.88m | 486.00 | -- | -- | -- | 0.216 | -1.23 | -1.23 | 1.81 | -2.42 | 0.4967 | 1.29 | 7.49 | 370,399.20 | -34.51 | -30.62 | -103.81 | -42.31 | 76.87 | 93.52 | -69.48 | -119.08 | 1.16 | -7.70 | -- | -- | 4.99 | -7.05 | 3.21 | -- | -20.67 | -- |
| Anebulo Pharmaceuticals Inc | 0.00 | -7.92m | 38.90m | 2.00 | -- | 20.49 | -- | -- | -0.306 | -0.306 | 0.00 | 0.0732 | 0.00 | -- | -- | 0.00 | -137.58 | -- | -154.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 30.09 | -- | -- | -- |
| LAVA Therapeutics NV | 7.40m | -24.18m | 38.91m | 37.00 | -- | 0.9077 | -- | 5.26 | -0.8976 | -0.8976 | 0.2741 | 1.63 | 0.0689 | -- | 3.23 | 199,946.00 | -22.51 | -- | -27.11 | -- | 97.78 | -- | -326.89 | -- | -- | -- | 0.1257 | -- | -65.09 | -- | -31.55 | -- | -- | -- |
| Iterum Therapeutics PLC | 0.00 | -30.55m | 40.19m | 14.00 | -- | -- | -- | -- | -2.00 | -2.00 | 0.00 | -0.5068 | 0.00 | -- | -- | 0.00 | -109.80 | -118.12 | -297.32 | -199.23 | -- | -- | -- | -890,554.10 | -- | -7.38 | 2.05 | -- | -- | -- | 13.64 | -- | -32.09 | -- |
Data as of Nov 22 2024. Currency figures normalised to Intensity Therapeutics Inc's reporting currency: US Dollar USD
11.99%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Sapient Capital LLCas of 30 Sep 2024 | 1.01m | 7.34% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 208.89k | 1.52% |
| Brown Advisory LLCas of 30 Sep 2024 | 148.11k | 1.08% |
| Geode Capital Management LLCas of 30 Sep 2024 | 64.35k | 0.47% |
| Sigma Planning Corp.as of 30 Sep 2024 | 47.74k | 0.35% |
| Mesirow Financial Investment Management, Inc.as of 30 Sep 2024 | 44.18k | 0.32% |
| William Blair Investment Management LLCas of 30 Sep 2024 | 37.81k | 0.28% |
| GTS Securities LLCas of 30 Sep 2024 | 37.29k | 0.27% |
| One Charles Private Wealth Services LLCas of 30 Sep 2024 | 31.80k | 0.23% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 20.26k | 0.15% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
